Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 3/2011

01-07-2011 | Review Article

Lymphedema and breast cancer: a review of the literature

Authors: Stamatakos Michael, Stefanaki Charikleia, Kontzoglou Konstantinos

Published in: Breast Cancer | Issue 3/2011

Login to get access

Abstract

Breast cancer continues to be the most common malignancy among women in the United States. Despite its high incidence, early detection and modern treatment have made long-term survival more common. One of the most important sequelae of the treatment of breast cancer is the development of lymphedema. There are many issues for women to deal with after treatment for breast cancer. Focusing on the quality of life after breast cancer means dealing with issues such as an altered body image, changes in relationships with partner and children, living with any ongoing side effects, and the fear of tumor recurrence. The objective of this paper is to elucidate these issues concerning lymphedema.
Literature
1.
Megens A, Harris SR. Physical therapist management of lymphedema following treatment for breast cancer: a critical review of its effectiveness. Phys Ther. 1998;78(2):1302–11.PubMed
2.
Harris SR, Niesen-Vertommen SL. Challenging the myth of exercise-induced lymphedema following breast cancer: a series of case reports. J Surg Oncol. 2000;74:95–9.PubMedCrossRef
3.
Brorson H. Liposuction in arm lymphedema treatment. Scand J Surg. 2003;92:287–95.PubMed
4.
Andersen L, Hojris I, Erlandsen M, Andersen J. Treatment of breast cancer-related lymphedema with or without manual lymphatic drainage. Acta Oncol. 2000;39:395–405.
5.
Reintgen DS, Cox CE, Puleo CA. Lymphedema in the post mastectomy patient: pathophysiology, prevention and management. In: Bland KI, Copeland EM, editors. The breast: comprehensive management of benign and malignant disease. 2nd ed. Philadelphia: W.B. Saunders Company; 1998. p. 1003–11.
6.
Gasbarro V, Michelini S, Antignani PL, Tsolaki E, Ricci M, Allegra C. The CEAP-L classification for lymphedemas of the limbs: the Italian experience. Int Angiol. 2009;28(4):315–24.PubMed
7.
8.
9.
Daane S, Poltoratszy P, Rockwell B. Postmastectomy lymphedema management: evolution of the complex decongestive therapy technique. Ann Plast Surg. 1998;40(2):128–34.PubMedCrossRef
10.
Brennan MJ, DePompolo RW, Garden FH. Focused review: post mastectomy lymphedema. Arch Phys Med Rehabil. 1996;77:S74–80.PubMedCrossRef
11.
Brennan MJ, Miller LT. Overview of treatment options and review of the current role and use of compression garments intermittent pumps, and exercise in the management of lymphedema. Cancer. 1998;83(12):2821–7.PubMedCrossRef
12.
Badger CM, Peacock JL, Mortimer PS. A randomized, controlled, parallel-group clinical trial comparing multilayer bandaging followed by hosiery versus hosiery alone in the treatment of patients with lymphedema of the limb. Cancer. 1998;83(12):2832–7.
13.
Szuba A, Achalu R, Rockson SG. Decongestive lymphatic therapy for patients with breast carcinoma-associated lymphedema. Cancer. 2002;95(11):2260–7.PubMedCrossRef
14.
Liu N. Trafficking of hyaluronan in the interstitium and its possible implications. Lymphology. 2004;37:6–14.PubMed
15.
Masmoudi A, Maaloul I, Turki H, Elloumi Y, Marrekchi S, Bouassida S, Ben Jemaa M, Zahaf A. Erysipelas after breast cancer treatment (26 cases). Dermatol Online J. 2005;11(3):12.PubMed
16.
Ocaña A, Delgado C, Rodríguez CA, Bellido L, Izquierdo N, Martín R, Cruz JJ. Case 3. Upper limb lymphangiosarcoma following breast cancer therapy. J Clin Oncol. 2006;24:1477–8.PubMedCrossRef
17.
18.
19.
Mayrovitz HN. The standard of care for lymphedema: current concepts and physiological considerations. Lymphat Res Biol. 2009;7(2):101–8.PubMedCrossRef
20.
Chen C, Crooks S, Keeley V, Mortimer P, Sitzia J, Todd J, et al. BLS clinical definitions. Sevenoaks: British Lymphology Society; 2001.
21.
Narushima M, Mihara M, Yamamoto Y, Iida T, Koshima I, Mundinger GS. The intravascular stenting method for treatment of extremity lymphedema with multi-configuration lymphaticovenous anastomoses. Plast Reconstr Surg. 2010;125(3):935–43.PubMedCrossRef
22.
Kissin MW, Querci della Rovere G, Easton D, Westbury G. Risk of lymphedema following the treatment of breast cancer. Br J Surg. 1986;73:580–4.PubMedCrossRef
23.
Suneson BL, Lindholm C, Hamrin E. Clinical incidence of lymphedema in breast cancer patients in Jonkoping County, Sweden. Eur J Cancer Care (Engl). 1996;5:7–12.CrossRef
24.
Querci della Rovere G, Ahmad I, Singh P, Ashley S, Daniels IR, Mortimer P. An audit of the incidence of arm lymphoedema after prophylactic level I/II axillary dissection without division of the pectoralis minor muscle. Ann R Coll Surg Eng. 2003;85:158–61.CrossRef
25.
van der Veen P, De Voogdt N, Lievens P, Duquet W, Lamote J, Sacre R. Lymphedema development following breast cancer surgery with full axillary resection. Lymphology. 2004;37:206–8.PubMed
26.
Larson D, Weinstein M, Goldberg I, Silver B, Recht A, Cady B, Silen W, Harris JR. Edema of the arm as a function of the extent of axillary surgery in patients with stage I–II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575–82.PubMedCrossRef
27.
Herd-Smith A, Russo A, Muraca MG, Del Turco MR, Cardona G. Prognostic factors for lymphedema after primary treatment of breast carcinoma. Cancer. 2001;92:1783–7.PubMedCrossRef
28.
Goffman TE, Laronga C, Wilson L, Elkins D. Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery. Breast J. 2004;10:405–11.PubMedCrossRef
29.
30.
Clark B, Sitzia J, Harlow W. Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. QJM. 2005;98:343–8.PubMedCrossRef
31.
Purushotham AD, Bennett Brighton TM, Klevesath MB, Chou P, Agbaje OF, Duffy SW. Lymph node status and breast cancer—related lymphedema. Ann Surg. 2007;246:42–5.PubMedCrossRef
32.
Stanton AW, Levick JR, Mortimer PS. Current puzzles represented by postmastectomy oedema (breast cancer related lymphoedema). Vasc Med. 1996;1:213–25.PubMed
33.
Aboul-Enein A, Eshmawy I, Arafa MS, Abboud A. The role of lymphovenous communication in the development of postmastectomy lymphedema. Surgery. 1983;95:562–5.
34.
Baumeister RG, Siuda S. Treatment of lymphoedemas by microsurgical lymphatic grafting: what is proved? Plast Reconstr Surg. 1990;85:64–74.PubMedCrossRef
35.
Foldi M. Lymphoedema. In: Foldi M, Casley-Smith JR, editors. Lymphangiology. Stuttgart: Schattauer; 1983. p. 667–82.
36.
Bates DO, Levick JR, Mortimer PS. Starling pressures in the human arm and their alteration in postmastectomy oedema. J Physiol. 1994;477:355–63.PubMed
37.
Williams A, Franks PJ, Moffatt CJ. Lymphoedema: estimating the size of the problem. Pall Med. 2005;19(4):300–13.CrossRef
38.
Casley-Smith JR, Casley-Smith JR. Volume alterations in lymphoedema; untreated, and after complex therapy (CP.T), benzo-pyrones, or both. Lymphology. 1994;27:627–31.
39.
Badger C, Preston N, Seers K, Mortimer P. Physical therapies for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2004;4:CD003141.PubMed
40.
Badger C, Preston N, Seers K, Mortimer P. Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev. 2003;4:CD003140.
41.
Moseley AL, Carati CJ, Piller NB. A systematic review of common conservative therapies for arm lymphoedema secondary to breast cancer treatment. Ann Oncol. 2007;18:639–46.PubMedCrossRef
42.
Bernas MJ, Witte CL, Witte MH. International Society of Lymphology Executive Committee. The diagnosis and treatment of peripheral lymphedema: draft revision of the 1995 consensus document of the International Society of Lymphology Executive Committee for Discussion at the September 3–7, 2001 XVIII International Congress of Lymphology in Genoa, Italy. Lymphology. 2001;34:84–91.PubMed
43.
Casley-Smith JR, Casley-Smith JR. Modern treatment for lymphoedema. 5th ed. Australia: Terrace Printing; 1997. p. 138–9.
44.
45.
Foldi M, Foldi E, Kubrik S. Textbook of lymphology for physicians and lymphedema therapists. Germany: Elsevier; 2003. p. 496–7.
46.
Piller NB, Packer R, Coffee J, Swagemakers S. Accepting responsibility for health management: partner training as an effective means of managing chronic lymphoedema. Prog Lymphol. 1996;XV:266–9.
47.
Ramlett AA. Pharmacologic aspects of phlebotropic drug in CVI-associated edema. Angiology. 2000;51(1):19–23.CrossRef
48.
Roztocil K, Pretovsky I, Olivia I. The effects of hydroethylrutosides on capillary filtration rate in the lower limbs of man. Eur J Clin Pharm. 1993;11:435–8.CrossRef
49.
Clement DL. Management of venous edema: insights from an international task force. Angiology. 2000;51(1):13–7.PubMedCrossRef
50.
Knight KR, Khazanchi RK, Pederson WC, McCann JJ, Coe SA, O’Brien BM. Coumarin and 7 hydroxycoumarin treatment of canine obstructive lymphoedema. Clin Sci (Lond). 1989;77(1):69–76.
51.
Lievens P. The effect of a combined HeNe and I.R. laser treatment on the regeneration of the lymphatic system during the process of wound healing. Lasers Med Sci. 1991;6(193):193–9.CrossRef
52.
Nakaji S, Shiroto C, Yodono M, Umeda T, Liu Q. Retrospective study of adjunctive diode laser therapy for pain attenuation in 662 patients: detailed analysis by questionnaire. Photomed Laser Surg. 2005;23(1):60–5.PubMedCrossRef
53.
Nouri K, Jimenez G, Harrison-Balestra C, Elgert G. 545-nm pulsed dye laser in the treatment of surgical scarring starting on the suture removal day. Dermatol Surg. 2003;29:65–73.PubMedCrossRef
54.
Yasuhara H, Shigematsu H, Muto T. A study of the advantages of elastic stockings for leg lymphoedema. Int Angiol. 1996;15:272–7.PubMed
55.
Johansson K, Tibe K, Kanne L, Skantz H. Controlled physical training for arm lymphedema patients. Lymphology. 2004;37:37–9.
56.
Hull MM. Functional and psychosocial aspects of lymphedema in women treated for breast cancer. Innov Breast Cancer Care. 1998;3(97–100):117–8.
57.
Tobin MB, Lacey HJ, Meyer L, Mortimer PS. The psychological morbidity of breast cancer-related arm swelling: psychological morbidity of lymphedema. Cancer. 1993;72:3248–52.PubMedCrossRef
58.
Armer JM, Fu M, Wainstock J, Zagar E, Jacobs LK. Lymphedema following breast cancer treatment, including sentinel lymph node biopsy. Lymphology. 2004;37:73–91.PubMed
59.
Armer J, Fu MR. Age differences in lymphedema symptom experience post-breast cancer treatment. Cancer Nurs. 2005;28(3):200–7.PubMedCrossRef
60.
Baron RH, Fey JV, Raboy S, Thaler HT, Borgen PI, Temple LK, Van Zee KJ. Eighteen sensations after breast cancer surgery: a comparison of sentinel lymph node biopsy and axillary lymph node dissection. Oncol Nurs Forum. 2002;29:651–9.PubMedCrossRef
61.
Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast cancer. Cancer. 2000;88:608–14.PubMedCrossRef
62.
Brennan M, Passik S. Lymphedema complicated by pain and psychological distress: a case with complex treatment needs. J Pain Symptom Manage. 1996;12:376–9.PubMedCrossRef
63.
Carter BJ. Women’s experiences of lymphedema. Oncol Nurs Forum. 1997;24(5):875–82.PubMed
64.
Passik SD, McDonald MV. Psychosocial aspects of upper extremity lymphedema in women treated for breast carcinoma. Cancer. 1998;83(12):2817–20.PubMedCrossRef
65.
Davis MA. Lymphedema following breast cancer treatment. Radio Technol. 1998;70:42–56.
66.
Hare M. The lived experience of breast cancer-related lymphedema. Nurs Stand. 2000;15(7):35–9.PubMed
67.
Woods M. Patient’s perceptions of breast cancer-related lymphedema. Eur J Cancer Care. 1993;2:125–8.CrossRef
68.
Passik SD, Newman M, Brennan M, Holland J. Psychiatric consultation for women undergoing rehabilitation for upper-extremity lymphedema following breast cancer treatment. J Pain Symptom Manage. 1993;8:226–33.PubMedCrossRef
69.
Velanovich V, Szymanski W. Quality of life of breast cancer patients with lymphedema. Am J Surg. 1999;177:184–8.PubMedCrossRef
70.
Shih YC, Xu Y, Cormier JN, Giordano S, Ridner SH, Buchholz TA, Perkins GH, Elting LS. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009;27:2007–14.PubMedCrossRef
71.
Fu MR. Post-breast cancer lymphedema and management. Recent Adv Res Updat. 2004;5(1):125–38.
72.
Humble CA. Lymphedema: incidence, pathophysiology, management, and nursing care. Contin Educ. 1995;22(10):1503–9.
73.
Loprinzi CL, Kugler JW, Sloan JA, Rooke TW, Quella SK, Novotny P, Mowat RB, Michalak JC, Stella PJ, Levitt R, Tschetter LK, Windschitl H. Lack of effect of coumarin in women with lymphedema after treatment for breast cancer. N Engl J Med. 1999;340:346–50.PubMedCrossRef
74.
Mason M. The treatment of lymphedema by complex physical therapy. Aust J Physiother. 1993;39(1):41–5.
75.
76.
Thiadens SR. Current status of education and treatment resources for lymphedema. Cancer. 1998;83(12):2864–8.PubMedCrossRef
77.
78.
Rose KE, Taylor HM, Twycross RG: Long-term compliance with treatment in obstructive arm lymphedema in cancer. Palliat Med. 1991;5:52–55.
79.
Boris M, Weidorf S, Lasinski B. Persistence of lymphedema reduction after noninvasive complex lymphedema therapy. Oncology. 1997;11(1):99–114.PubMed
80.
Boyages J, Barraclough B, Middledorp J, Gorman D, Langlands AO. Early breast cancer: cosmetic and functional results after treatment by conservative techniques. Aust N Z J Surg. 1988;58:111–21.PubMedCrossRef
81.
Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, Bryan CJ, Williams-Smith CT, Greene QP. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009;361(7):664–73.PubMedCrossRef
82.
Petrek JA, Lerner R, et al. Lymphedema. In: Harris JR, Lippman ME, editors. Diseases of the breast. Philadelphia: Lippincott–Raven; 1996. p. 896–903.
83.
Torres Lacomba M, Yuste Sánchez MJ, Zapico Goñi A, Prieto Merino D, Mayoral del Moral O, Cerezo Téllez E, Minayo Mogollón E. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010;340:b5396.PubMedCrossRef
Metadata
Title
Lymphedema and breast cancer: a review of the literature
Authors
Stamatakos Michael
Stefanaki Charikleia
Kontzoglou Konstantinos
Publication date
01-07-2011
Publisher
Springer Japan
Published in
Breast Cancer / Issue 3/2011
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-010-0246-1

Other articles of this Issue 3/2011

Breast Cancer 3/2011 Go to the issue

Case Report

Parenchymal leiomyoma of the breast: a case report with special reference to magnetic resonance imaging findings and an update review of literature

Erratum

Erratum to: Lymphedema and breast cancer: a review of the literature

Original Article

Preoperative and intraoperative predictors of positive margins after breast-conserving surgery: a retrospective review

Special Feature

Mammography and ultrasound features of triple-negative breast cancer

Original Article

Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial

Special Feature

Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits